ライフサイエンスコーパス: long-term survival rate

1 glioma model demonstrated a greater than 25% long-term survival rate.

2 tein expression was associated with a better long-term survival rate.

3 e surgical mortality rate but did affect the long-term survival rate.

4 factory sniff responses were associated with long-term survival rates.

5 Early-stage diagnosis is important for long-term survival rates.

6 ent with advanced disease, resulting in poor long-term survival rates.

7 hapes up the association between frailty and long-term survival rates.

8 oradiotherapy has also been shown to improve long-term survival rates.

9 ciated with an improvement in recurrence and long-term survival rates.

10 for low NT rates, mild NT severity, and low long-term survival rates.

11 ponse to cytotoxic therapy can contribute to long-term survival rates.

12 transplant recipients is associated with low long-term survival rates.

13 re healthy and fertile, and displayed normal long-term survival rates.

14 Endpoints were short- and long-term survival rates.

15 s alone are not sufficient to achieve better long-term survival rates.

16 Surgery, however, may result in improved long-term survival rates.

17 late with poor quality of life and decreased long-term survival rates.

18 Improved long-term survival rates after allogeneic hematopoietic

19 In Western populations, long-term survival rates after curative resection of gas

20 ndomized clinical trials have suggested that long-term survival rates after percutaneous coronary int

21 We sought to determine the long-term survival rates and defect-related morbidity of

22 ciated with high recurrence, metastasis, low long-term survival rates and poor treatment outcome.

23 e among children with rhabdomyosarcoma, with long-term survival rates approaching 70%.

24 Complete remission and long-term survival rates are low for older adults treate

25 , perioperative morbidity and mortality, and long-term survival rates as patients undergoing initial

26 Long-term survival rates at 1, 5, and 8 years were highe

27 We aimed to clarify octogenarian long-term survival rates by stratifying revascularizatio

28 This allows for long-term survival rates currently ranging between 75% a

29 ve management is associated with an improved long-term survival rate, decreased cardiac mortality, an

30 The low long-term survival rate emphasizes the priority of clini

31 The long-term survival rate for patients whose HCC was detec

32 Long-term survival rates for children with acute lymphob

33 Long-term survival rates for older patients with newly d

34 ters for adenocarcinoma of the pancreas, and long-term survival rates for other periampullary tumors

35 ng a combination of platinum and paclitaxel, long-term survival rates for patients with advanced epit

36 Although short- and long-term survival rates have improved significantly, on

37 However, the long-term survival rates have remained very low.

38 and medical management have greatly improved long-term survival rates in patients with congenital hea

39 leads to sustained disease control and high long-term survival rates in patients with early-stage LP

40 es have shown that dental implants have high long-term survival rates, indicating their effectiveness

41 Despite this, the overall long-term survival rate is greater than 90%, which sugge

42 therapies have limited effectiveness and the long-term survival rate is low.

43 st curable pediatric and adult cancers, with long-term survival rates now exceeding 90% after treatme

44 ociated collagen signature-3 (TACS-3) to the long-term survival rate of human patients.

45 4-1BB activation) significantly improves the long-term survival rate of large tumor-bearing mice.

46 ith 4-1BB costimulation greatly improved the long-term survival rate of mice bearing large tumors and

47 Pancreatic cancer is associated with a poor long-term survival rate of only 10% to 15% after resecti

48 is for patients with localized osteosarcoma; long-term survival rates of less than 20% improved to 65

49 gnancy of the bone having poor prognosis and long-term survival rates of less than 30% in patients wi

50 of a dialysis-like treatment and may improve long-term survival rates of ovarian cancer patients.

51 To compare long-term survival rates of patients with first, primary

52 Enhanced long-term survival rates of young women with cancer and

53 r, there has been no significant increase in long-term survival rates over the past 30 years.

54 plus cisplatin is feasible with a reasonable long-term survival rate, particularly for patients who c

55 relapse with recurrent disease, after which long-term survival rates remain low.

56 or patients with end-stage lung disease, but long-term survival rates remain suboptimal compared with

57 dies showed significant median, overall, and long-term survival rates, suggesting optimal control of

58 tes are not necessarily associated with high long-term survival rates, suggesting that regimens may n

59 episode of mild AKI have significantly lower long-term survival rates than critically ill patients wi

60 nificantly lower recurrence rates and higher long-term survival rates than other existing treatment m

61 an ablative dose of RT for large IHCCs, with long-term survival rates that compare favorably with res

62 The long-term survival rate was similar between the two rese

63 outcome, resectability rate, pathology, and long-term survival rate were compared with 690 concurren

64 Overall local response rates and long-term survival rates were assessed.

65 Long-term survival rates were better, and fibrosis score

66 Long-term survival rates were comparably low between gro

67 In contrast, long-term survival rates were higher for patients with e

68 crowns and fixed dental prostheses have high long-term survival rates when inserted with conventional